Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Non-Current Assets (2019 - 2025)

Biodesix (BDSX) has disclosed Non-Current Assets for 7 consecutive years, with $55.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Assets fell 4.85% year-over-year to $55.0 million, compared with a TTM value of $55.0 million through Dec 2025, down 4.85%, and an annual FY2025 reading of $55.0 million, down 4.85% over the prior year.
  • Non-Current Assets was $55.0 million for Q4 2025 at Biodesix, down from $55.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $59.4 million in Q4 2023 and bottomed at $32.5 million in Q4 2021.
  • Average Non-Current Assets over 5 years is $47.9 million, with a median of $53.7 million recorded in 2023.
  • The sharpest move saw Non-Current Assets decreased 7.0% in 2021, then skyrocketed 50.14% in 2023.
  • Year by year, Non-Current Assets stood at $32.5 million in 2021, then grew by 21.82% to $39.6 million in 2022, then surged by 50.14% to $59.4 million in 2023, then dropped by 2.78% to $57.8 million in 2024, then dropped by 4.85% to $55.0 million in 2025.
  • Business Quant data shows Non-Current Assets for BDSX at $55.0 million in Q4 2025, $55.3 million in Q3 2025, and $55.3 million in Q2 2025.